Search Results - Valerio Alonzi
- Showing 1 - 2 results of 2
-
1
Long-Term Follow-Up of Patients With Idiopathic Pulmonary Fibrosis Treated With Pirfenidone or Nintedanib: A Real-Life Comparison Study by Paolo Cameli, Rosa Metella Refini, Laura Bergantini, Miriana d’Alessandro, Valerio Alonzi, Carlo Magnoni, Paola Rottoli, Piersante Sestini, Elena Bargagli
Published 2020Artigo -
2
Serum KL‐6 concentrations as a novel biomarker of severe COVID‐19 by Miriana d’Alessandro, Paolo Cameli, Rosa Metella Refini, Laura Bergantini, Valerio Alonzi, Nicola Lanzarone, David Bennett, Giuseppe Domenico Rana, Francesca Montagnani, Sabino Scolletta, Federico Franchi, Bruno Frediani, Serafina Valente, Maria Antonietta Mazzei, Francesco Bonella, Elena Bargagli
Published 2020Artigo
Search Tools:
Related Subjects
Gastroenterology
Internal medicine
Lung
Medicine
Adverse effect
Biochemistry
Biology
Biomarker
Coronavirus
Coronavirus disease 2019 (COVID-19)
Discontinuation
Disease
Idiopathic pulmonary fibrosis
Immunology
Infectious disease (medical specialty)
Interquartile range
Lymphocyte
Nintedanib
Pirfenidone
Respiratory system
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Severity of illness
Tolerability